Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
research in several areas. Learning activities will focus on: The development and characterization of animal models and/or microphysiological systems for viral agents. Emphasis is placed on determining
-
subareas include, but are not limited to: procedural content generation, intelligent non-player characters and agents, adaptive and personalized gameplay, narrative in games, AI for content and/or design
-
-leading expertise in nutrition, food, and plant sciences to discover and deliver innovative plant-based strategies for advancing human health. PHHI is unique in that it supports an in-house outreach
-
. Position Overview Division of Bioinformatics and Computational Biology (DBCB, https://medicine.osu.edu/departments/biomedical-informatics/divisions/division-of-bioinformatics-and-computational-biology
-
more “AI-ready” designs? In this context, GenAI-based assistants (for understanding manuals, procedures, and logs) and agentic AI (for decomposing high-level operational goals into safe, ordered
-
, develop and execute workshops and projects based on direction, needs, and input from the committee. This GSSA position is ideal for those who are interested in needs assessment, program development
-
, Uncertainty, and Dynamics.” About the Project Market interaction is increasingly automated by artificial learning agents. Examples include pricing agents in electronic retail or bidding agents in display
-
offer components are subject to additional approvals based on UC policy. Your placement within the salary range is dependent on a number of factors including your work experience and internal equity
-
, evidence-based treatment plans in dynamic critical care environments. Prescribes and titrates pharmacologic agents (including vasoactive infusions / vasopressors, sedatives, analgesics, paralytics
-
to cancer therapeutics, target identification, mechanism-based pharmacology, or chemoprevention. We have a special interest in candidates focused on the development of novel agents for cancer-associated pain